Evaluation the Role of Malondialdehyde in Myocardial Infarction Patients

Abstract

Case control study was carried out in Kirkuk city in the intensive care unit in Kirkuk general hospital from
Feb 2020 to May 2020. The study included 90 individuals including sixty myocardial infraction patients
and thirty healthy individuals to evaluate the level of Malondialdehyde (MDA) in myocardial infraction
patients and healthy controls. All patients were aged between (40-80) years, with a negative family history
of heart attack. Blood samples were collected from each patients and controls to evaluate the levels of
malondialdehyde by using immunofluorescence technique. The study showed no significant differences
between myocardial infraction patients and control groups regarding their age, although 33.33% of MI
patients belonged to the age group 60-69 year flowed by 28.33% in the age group 50-59 year. The study
displayed that the highest mean of MDA was recorded in MI (104.7±13.0 ng/ml) as compared with the
control group (66.7± 22.7 ng/ml), The result was significant (P: < 0.05). The study concluded that, The
study displayed that the MDA levels were elevated significantly in patients group as compared with the
control group and MDA is may be an important cardiovascular parameter, which may be followed before
and during the disease.